Tempest Therapeutics shares surge 17.65% after-hours after completing Factor Bioscience CAR-T asset acquisition, adding next-gen therapies.

Tempest Therapeutics (NASDAQ:TPST) surged 17.65% in after-hours trading following the announcement that it completed the all-stock acquisition of Factor Bioscience Inc.’s dual-targeting CAR-T assets, including TPST-2003, a clinical-stage CD-19/BCMA therapy. The transaction, approved at the company’s annual shareholder meeting, expands Tempest’s pipeline with next-generation CAR-T programs and adds Matt Angel as CEO, who emphasized the potential of the pipeline to address solid tumors and hematologic malignancies. The deal, valued at a low cost given Tempest’s $11.6 million market cap, also secures strategic funding for TPST-2003’s development, with a planned 2027 BLA submission in China and U.S. registration studies. The acquisition, coupled with existing Phase 3 readiness for amezalpat (TPST-1120) and a $27 million cash runway through mid-2027, likely fueled investor optimism about near-term value creation milestones.